Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Apr 30:49:59-61.
doi: 10.1016/j.jdcr.2024.04.032. eCollection 2024 Jul.

Discoid lupus erythematosus successfully treated with deucravacitinib

Nnenna Ezeh  1 , Ruth Ann Vleugels  2 , Neda Shahriari  2
Affiliations
Case Reports

Discoid lupus erythematosus successfully treated with deucravacitinib

Nnenna Ezeh et al. JAAD Case Rep. .
No abstract available

Keywords: TYK-2 inhibitor; cutaneous lupus erythematosus; deucravacitinib; discoid lupus erythematosus; emerging treatments; interferon.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Clinical findings prior to treatment. Multiple quarter-sized plaques of alopecia with areas of hypopigmentation, scaly erythema with follicular keratotic plugs, and peripheral hyperpigmentation on the scalp indicative of active inflammation. A, Left frontal parietal scalp lesion (red arrow). B, Left posterior parietal scalp lesion (white arrow).
Fig 2
Fig 2
Clinical findings 1 month after initiation of deucravacitinib. There is clearance of scalp erythema and follicular keratotic plugs indicating resolution of inflammation. A, Left frontal parietal scalp lesion (red arrow). B, left posterior parietal scalp lesion (white arrow).
See this image and copyright information in PMC

References

    1. Shaw K., Sanchez-Melendez S., Taylor D., et al. Assessment of clinical response to anifrolumab in patients with refractory discoid lupus erythematosus. JAMA Dermatol. 2023;159(5):560. doi: 10.1001/jamadermatol.2023.0175. - DOI - PMC - PubMed
    1. Strober B., Thaçi D., Sofen H., et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40–51. doi: 10.1016/j.jaad.2022.08.061. - DOI - PubMed
    1. Imafuku S., Okubo Y., Tada Y., et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, phase 3 trial. J Dermatol. 2024;51(3):365–379. doi: 10.1111/1346-8138.17074. - DOI - PMC - PubMed
    1. Morand E., Pike M., Merrill J.T., et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75(2):242–252. doi: 10.1002/art.42391. - DOI - PMC - PubMed
    1. Zhang A., Gaffney R.G., Merola J.F. Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib. JAAD Case Rep. 2024;45:110–112. doi: 10.1016/j.jdcr.2023.11.029. - DOI - PMC - PubMed

Publication types

LinkOut - more resources